title: [Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD].
abstract: BACKGROUND
  The effect of the vascular endothelial growth factor (VEGF) inhibitors triamcinolone and bevacizumab (Avastin) on serous pigment epithelial detachment (PED) related to age-dependent macular degeneration (AMD) was analysed retrospectively.
  
  
  METHODS
  Data of 45 patients (45 eyes) were evaluated: 11 patients received an intravitreal injection with triamcinolone and 16 with bevacizumab. The remaining 18 patients received no therapy. Visual acuity (VA), height of the PED, retinal thickness and the cystoid component of the PED were compared after 6 months follow-up.
  
  
  RESULTS
  Over 90% showed a stabilisation or improvement in VA after bevacizumab therapy; 63% of those who received triamcinolone showed VA stabilisation. Patients who received no therapy had a significant decrease in VA.
  
  
  CONCLUSIONS
  Our data seem to implicate that VA outcome is much better after bevacizumab treatment. VA outcome seems to correlate with the cystoid component of the foveal oedema rather than with the height of PED. A greater number of patients with a longer period of follow-up are necessary to confirm these results.
authors.affiliation: Augenklinik, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Hegewischstr. 2, 24105, Kiel, Deutschland. afrimpong@ophthalmol.uni-kiel.de
authors.forename: A
authors.initials: A
authors.lastname: Frimpong-Boateng
authors.forename: M A
authors.initials: MA
authors.lastname: Varde
authors.forename: F
authors.initials: F
authors.lastname: Rüfer
authors.forename: A
authors.initials: A
authors.lastname: Bunse
authors.forename: J
authors.initials: J
authors.lastname: Roider
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D012163:Retinal Detachment / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage*; D014822:Vitreous Body / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014221:Triamcinolone; D000068258:Bevacizumab